tradingkey.logo
tradingkey.logo
Suchen

Aspire Biopharma Holdings Inc

ASBP
Zur Watchlist hinzufügen
6.210USD
+0.350+5.97%
Handelsschluss 07/02, 13:00ETKurse um 15 Minuten verzögert
1.04MMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Aspire Biopharma Holdings Inc Unternehmen

Aspire Biopharma Holdings, Inc. is an early-stage biopharmaceutical company. It develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. It has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. It also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.

Aspire Biopharma Holdings Inc Informationen

BörsenkürzelASBP
Name des UnternehmensAspire Biopharma Holdings Inc
IPO-datumFeb 18, 2022
CEO- -
Anzahl der mitarbeiter- -
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 18
Addresse194 Candelaro Drive, #233
StadtHUMACAO
BörseNASDAQ OMX - NASDAQ BASIC
LandPuerto Rico
Postleitzahl00791
Telefon
Website
BörsenkürzelASBP
IPO-datumFeb 18, 2022
CEO- -

Führungskräfte von Aspire Biopharma Holdings Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kraig Higginson
Mr. Kraig Higginson
Executive Chairman of the Board
Executive Chairman of the Board
8.78K
--
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
333.00
--
Mr. Donald G. Fell
Mr. Donald G. Fell
Independent Director
Independent Director
--
--
Mr. Ernest J. Scheidemann, Jr.
Mr. Ernest J. Scheidemann, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Barbara J. Sher
Ms. Barbara J. Sher
Director
Director
--
--
DR. Edward Kimball
DR. Edward Kimball
Director
Director
--
--
Mr. Surendra Ajarapu
Mr. Surendra Ajarapu
Director
Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. Kraig Higginson
Mr. Kraig Higginson
Executive Chairman of the Board
Executive Chairman of the Board
8.78K
--
Mr. Howard A. Doss, CPA
Mr. Howard A. Doss, CPA
Director
Director
333.00
--
Mr. Donald G. Fell
Mr. Donald G. Fell
Independent Director
Independent Director
--
--
Mr. Ernest J. Scheidemann, Jr.
Mr. Ernest J. Scheidemann, Jr.
Chief Financial Officer
Chief Financial Officer
--
--
Ms. Barbara J. Sher
Ms. Barbara J. Sher
Director
Director
--
--
DR. Edward Kimball
DR. Edward Kimball
Director
Director
--
--

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Aspire Biopharma Holdings Inc?

Die fünf größten Anteilseigner von Aspire Biopharma Holdings Inc sind: Mr. Kraig Higginson

Wie viele Institutionen halten Anteile an Aspire Biopharma Holdings Inc (ASBP)?

Mit Stand vom 2026Q1 halten 66 Institutionen Anteile an Aspire Biopharma Holdings Inc, mit einem Gesamtmarktwert von etwa 555.77K, was 11.06% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 360574.00 gestiegen.